

Significant events in **respiratory syncytial virus (RSV)** vaccination practice in Australia

Year	Month	Intervention
2023	November	First recombinant neutralising human immunoglobulin G1 kappa (IgG1κ) long-acting monoclonal antibody, nirsevimab (Beyfortus), registered for use in neonates and children up to 24 months of age for RSV protection through passive immunisation
2024	January	First RSV vaccine – adjuvanted recombinant RSV pre-fusion F protein vaccine (Arexvy) – registered for use in individuals aged ≥60 years
	February	Arexvy made available through private prescription
	March	<p>Second RSV vaccine – bivalent recombinant RSV pre-fusion F protein vaccine (Abrysvo) – registered for use in pregnant women between 24 and 36 weeks gestation and individuals aged ≥60 years</p> <p>NSW Health RSV Vulnerable Babies Program provides free nirsevimab for medically at-risk infants and young children from March to September</p> <p>ATAGI recommends:</p> <ul style="list-style-type: none"> a single dose of RSV vaccine for: <ul style="list-style-type: none"> adults aged ≥75 years Aboriginal and Torres Strait Islander people aged ≥60 years adults aged ≥60 years who have a medical condition that increases the risk of severe RSV disease pregnant women at 28–36 weeks' gestation a single dose of nirsevimab for neonates and infants aged <8 months whose mothers were not vaccinated at least two weeks before delivery or who are at increased risk of severe RSV disease
	April	<p>Queensland Paediatric Respiratory Syncytial Virus Prevention (QPRSVP) Program provides free nirsevimab for all newborn infants and medically at-risk young children</p> <p>Western Australia RSV infant immunisation program provides free nirsevimab for all newborn infants and medically at-risk young children from April to September</p> <p>Nirsevimab not available outside of state-funded programs in 2024</p>
	June	<p>RSV chapter of the <i>Australian Immunisation Handbook</i> published to provide clinical information and recommendations for use of RSV immunisation products</p> <p>Abrysvo available on private prescription</p>
2025	February	<p>Maternal RSV immunisation program provides free Abrysvo under the NIP for pregnant women at 28–36 weeks gestation (prior to 37 weeks) to protect their baby</p> <p>Additionally, states and territories provide nirsevimab for free under neonate or catch-up programs in 2025 to eligible infants and children including:</p> <ul style="list-style-type: none"> infants up to 8 months: <ul style="list-style-type: none"> whose mother did not receive the RSV vaccine during pregnancy who were born within 2 weeks after the mother receiving an RSV vaccine who have a condition or circumstance that increases their risk of severe RSV disease young children aged 8 months to under 2 years who have certain risk conditions for severe RSV disease are recommended to receive the RSV immunisation product before their second RSV season
	March	<p>First mRNA RSV F protein vaccine (mRESVIA) registered for use in adults ≥60 years of age</p> <p>Age for which Arexvy indicated for use extended to include individuals 50–59 years who are at increased risk for RSV disease</p>

Year	Month	Intervention
2025	July	Victoria's older adult RSV program provides free Arexvy to residents aged ≥ 60 years in public and Aboriginal and Torres Strait Islander community-controlled aged care services